{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:54:20Z","timestamp":1794329660515,"version":"4.9.0"},"reference-count":117,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic, symmetric polyarticular synovitis, with a global prevalence of approximately 0.5%-1%. Its pathogenesis involves a complex interplay of genetic and environmental factors, as well as abnormal immune activation. RA patients face a significantly increased risk of cardiovascular disease, with atherosclerosis (AS) and its complications being the leading cause of mortality. Chronic systemic inflammation has long been considered the core pathological bridge linking RA and AS, whereby inflammatory cytokines drive cardiovascular events by impairing endothelial function and promoting arterial plaque formation and destabilization. However, recent research has yielded critical breakthroughs, revealing that dyslipidemia plays a vital role in RA pathogenesis and its comorbidity with AS. It goes beyond a traditional secondary effect, serving as an active participant intertwined with the immune-inflammatory network. This review specifically focuses on lipid-immune crosstalk in RA-AS comorbidity. To this end, we aim to systematically outline the epidemiological evidence for this association, summarize current clinical management strategies and their impact on cardiovascular risk, analyze shared risk factors, and explore in depth the central role of lipid metabolism in their shared pathophysiological mechanisms. We focus on cutting-edge topics such as the \u201clipid paradox\u201d phenomenon, lipoprotein dysfunction, lipid metabolic dysregulation in macrophages and the imbalance of bioactive lipid mediators to provide a comprehensive perspective and theoretical basis for understanding their common pathophysiological pathways and developing novel therapeutic strategies targeting the metabolism-immune axis.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1790634","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:43:27Z","timestamp":1776059007000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Lipid metabolism at the intersection of rheumatoid arthritis and atherosclerosis"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiaomei","family":"Fang","sequence":"first","affiliation":[{"name":"Department of Critical Care Medicine, Guangzhou University of Chinese Medicine Dongguan Hospital","place":["Dongguan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqi","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Yang","sequence":"additional","affiliation":[{"name":"Fifth Clinical Medical College, Guangzhou University of Chinese Medicine","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanying","family":"Du","sequence":"additional","affiliation":[{"name":"College of Basic Medicine, Guangzhou University of Chinese Medicine","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shushu","family":"Wang","sequence":"additional","affiliation":[{"name":"Chinese Medicine Guangdong Laboratory, Guangzhou University of Chinese Medicine","place":["Zhuhai, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaole","family":"Yang","sequence":"additional","affiliation":[{"name":"Second Clinical Medical College, Guangzhou University of Chinese Medicine","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianfeng","family":"Lao","sequence":"additional","affiliation":[{"name":"Second Clinical Medical College, Guangzhou University of Chinese Medicine","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wensheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Shi","sequence":"additional","affiliation":[{"name":"Shantou Central Hospital, Shantou Clinical Medical College of Jinan University","place":["Shantou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Tian","sequence":"additional","affiliation":[{"name":"Dongguan Hospital, Guangzhou University of Chinese Medicine","place":["Dongguan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Biology and Food Engineering, Suzhou University of Technology","place":["Changshu, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangming","family":"Pan","sequence":"additional","affiliation":[{"name":"Shenzhen Hospital, Beijing University of Chinese Medicine","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunping","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]},{"name":"Department of Cardiovascular Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.02.006","article-title":"Immunopathogenesis of rheumatoid arthritis","volume":"46","author":"Firestein","year":"2017","journal-title":"Immunity"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12829","article-title":"Autoantibodies and B cells: The ABC of rheumatoid arthritis pathophysiology","volume":"294","author":"Volkov","year":"2020","journal-title":"Immunol Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1250884","article-title":"Metabolic changes in fibroblast-like synoviocytes in rheumatoid arthritis: State of the art review","volume":"15","author":"Hu","year":"2024","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102925","article-title":"Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: Symptomatic and non-symptomatic events in rheumatoid arthritis and systemic lupus erythematosus","volume":"21","author":"Restivo","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-00969-7","article-title":"Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease","volume":"19","author":"Weber","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1254753","article-title":"Dyslipidemia in rheumatoid arthritis: The possible mechanisms","volume":"14","author":"Yan","year":"2023","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1190607","article-title":"Lipid metabolism and rheumatoid arthritis","volume":"14","author":"Lei","year":"2023","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2023.105683","article-title":"Lipid profile and NT-proBNP changes from pre-clinical to established rheumatoid arthritis: A 12 years follow-up explorative study","volume":"91","author":"Raadsen","year":"2024","journal-title":"Joint Bone Spine"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.jacl.2017.05.009","article-title":"High triglycerides and low high-density lipoprotein cholesterol lipid profile in rheumatoid arthritis: A potential link among inflammation, oxidative status, and dysfunctional high-density lipoprotein","volume":"11","author":"Rodriguez-Carrio","year":"2017","journal-title":"J Clin Lipidol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21165883","article-title":"Association of electronegative LDL with macrophage foam cell formation and CD11c expression in rheumatoid arthritis patients","volume":"21","author":"Chang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/art.24092","article-title":"Risk of cardiovascular mortality in patients with rheumatoid arthritis: A meta-analysis of observational studies","volume":"59","author":"Avina-Zubieta","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180726","article-title":"Cardiovascular event risk in rheumatoid arthritis compared with type 2 diabetes: A 15-year longitudinal study","volume":"47","author":"Agca","year":"2020","journal-title":"J Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003488","article-title":"Moderate and high disease activity levels increase the risk of subclinical atherosclerosis progression in early rheumatoid arthritis: A 5-year prospective study","volume":"10","author":"Meng","year":"2024","journal-title":"RMD Open"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23106","article-title":"Association of anti-citrullinated peptide antibodies with coronary artery calcification in rheumatoid arthritis","volume":"69","author":"Geraldino-Pardilla","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/art.41381","article-title":"Anti-citrullinated protein antibody specificities, rheumatoid factor isotypes, and incident cardiovascular events in patients with rheumatoid arthritis","volume":"72","author":"Westerlind","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.122226","article-title":"Explaining the cardiovascular risk associated with rheumatoid arthritis: Traditional risk factors versus markers of rheumatoid arthritis severity","volume":"69","author":"Solomon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00211-4","article-title":"Global, regional, and national burden of rheumatoid arthritis, 1990-2020, and projections to 2050: A systematic analysis of the Global Burden of Disease Study 2021","volume":"5","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2025-005464","article-title":"Influence of body mass index on cardiovascular risk in rheumatoid arthritis varies across anti-citrullinated protein antibody status and biologic use","volume":"11","author":"Karpouzas","year":"2025","journal-title":"RMD Open"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170361","article-title":"Metabolic syndrome and its components among rheumatoid arthritis patients: A comprehensive updated systematic review and meta-analysis","volume":"12","author":"Hallajzadeh","year":"2017","journal-title":"PloS One"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf263","article-title":"The Fibrosis-4 Index (FIB-4) correlates with cardiovascular risk and insulin resistance in patients with rheumatoid arthritis","volume":"64","author":"Ferraz-Amaro","year":"2025","journal-title":"Rheumatol (Oxford)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06587-8","article-title":"Vascular effects of biologic and targeted synthetic antirheumatic drugs approved for rheumatoid arthritis: A systematic review","volume":"42","author":"Gerganov","year":"2023","journal-title":"Clin Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22091","article-title":"Lipid and lipoprotein levels and trend in rheumatoid arthritis compared to the general population","volume":"65","author":"Liao","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/nu16050653","article-title":"High-density lipoprotein metabolism and function in cardiovascular diseases: What about aging and diet effects","volume":"16","author":"Morvaridzadeh","year":"2024","journal-title":"Nutrients"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/art.41613","article-title":"Divergence of cardiovascular biomarkers of lipids and subclinical myocardial injury among rheumatoid arthritis patients with increased inflammation","volume":"73","author":"Weber","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201228","article-title":"HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab","volume":"72","author":"Raterman","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204987","article-title":"Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: Data from the National Veterans Health Administration","volume":"75","author":"Navarro-Millan","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2025.101002","article-title":"Cardiovascular disease risk factors in newly diagnosed rheumatoid arthritis: A retrospective cohort study","volume":"22","author":"Aronov","year":"2025","journal-title":"Am J Prev Cardiol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12051083","article-title":"Contribution of elevated glucose and oxidized LDL to macrophage inflammation: A role for PRAS40\/Akt-dependent shedding of soluble CD14","volume":"12","author":"Sanjurjo","year":"2023","journal-title":"Antioxidants (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1161\/01.atv.20.2.290","article-title":"Macrophage scavenger receptor class A: A multifunctional receptor in atherosclerosis","volume":"20","author":"de Winther","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-2275(20)40052-5","article-title":"Greater oxidative susceptibility of the surface monolayer in small dense LDL may contribute to differences in copper-induced oxidation among LDL density subfractions","volume":"36","author":"Tribble","year":"1995","journal-title":"J Lipid Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90144-e","article-title":"Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B","volume":"94","author":"Chait","year":"1993","journal-title":"Am J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212647","article-title":"Hypermetabolic macrophages in rheumatoid arthritis and coronary artery disease due to glycogen synthase kinase 3b inactivation","volume":"77","author":"Zeisbrich","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200493","article-title":"Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis","volume":"71","author":"Charles-Schoeman","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2024.06.016","article-title":"Challenges and advances in the management of inflammation in atherosclerosis","volume":"71","author":"Xing","year":"2025","journal-title":"J Adv Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.09.008","article-title":"Monocyte-macrophages and T cells in atherosclerosis","volume":"47","author":"Tabas","year":"2017","journal-title":"Immunity"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.841545","article-title":"Modified lipoproteins induce arterial wall inflammation during atherogenesis","volume":"9","author":"Lorey","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.yjmcc.2015.04.003","article-title":"Resolvin D1 activates the inflammation resolving response at splenic and ventricular site following myocardial infarction leading to improved ventricular function","volume":"84","author":"Kain","year":"2015","journal-title":"J Mol Cell Cardiol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-023-01816-3","article-title":"Increased n-6 polyunsaturated fatty acids indicate pro- and anti-inflammatory lipid modifications in synovial membranes with rheumatoid arthritis","volume":"46","author":"Mustonen","year":"2023","journal-title":"Inflammation"},{"key":"B39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nri.2015.4","article-title":"Specialized pro-resolving mediators: Endogenous regulators of infection and inflammation","volume":"16","author":"Basil","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13075-020-2133-2","article-title":"Resolvin D1 suppresses pannus formation via decreasing connective tissue growth factor caused by upregulation of miRNA-146a-5p in rheumatoid arthritis","volume":"22","author":"Sun","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.10.008","article-title":"Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease","volume":"76","author":"Castaner","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1409653","article-title":"Triglyceride-rich lipoproteins and cardiovascular diseases","volume":"15","author":"Xu","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s40119-020-00177-4","article-title":"Lipoprotein(a) and cardiovascular disease prevention across diverse populations","volume":"9","author":"Pearson","year":"2020","journal-title":"Cardiol Ther"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): A genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: A scientific statement from the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/eci.70127","article-title":"Lipoprotein(a) in clinical practice: Risk stratification and therapeutic strategies","volume":"56","author":"Nasrallah","year":"2026","journal-title":"Eur J Clin Invest"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102815","article-title":"Lipoprotein oxidation may underlie the paradoxical association of low cholesterol with coronary atherosclerotic risk in rheumatoid arthritis","volume":"129","author":"Karpouzas","year":"2022","journal-title":"J Autoimmun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Investigators","year":"2011","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.03.005","article-title":"Effect of ANGPTL3 inhibition with solbinsiran in preclinical and early human studies","volume":"85","author":"Ray","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00507-0","article-title":"Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): A double-blind, randomised, placebo-controlled, phase 2 trial","volume":"405","author":"Ray","year":"2025","journal-title":"Lancet"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.02.032","article-title":"Effects of Icosapent Ethyl on total ischemic events: From REDUCE-IT","volume":"73","author":"Bhatt","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.120899","article-title":"Smoking is a major preventable risk factor for rheumatoid arthritis: Estimations of risks after various exposures to cigarette smoke","volume":"70","author":"Kallberg","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-018-0360-5","article-title":"Smoking and susceptibility to rheumatoid arthritis in a Swedish population-based case-control study","volume":"33","author":"Hedstrom","year":"2018","journal-title":"Eur J Epidemiol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.08.013","article-title":"SASH1, a new potential link between smoking and atherosclerosis","volume":"242","author":"Weidmann","year":"2015","journal-title":"Atherosclerosis"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-016-3464-9","article-title":"The metabolic profile in early rheumatoid arthritis: A high prevalence of metabolic obesity","volume":"37","author":"Muller","year":"2017","journal-title":"Rheumatol Int"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30084-1","article-title":"Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: A position statement","volume":"7","author":"Neeland","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/164_2020_363","article-title":"Novel adipose tissue targets to prevent and treat atherosclerosis","volume":"270","author":"Scheja","year":"2022","journal-title":"Handb Exp Pharmacol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex414","article-title":"High prevalence of diabetes in patients with rheumatoid arthritis: Results from a questionnaire survey linked to claims data","volume":"57","author":"Albrecht","year":"2018","journal-title":"Rheumatol (Oxford)"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1002\/art.39195","article-title":"Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: A Consortium of Rheumatology Researchers of North America Registry study","volume":"67","author":"Solomon","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-024-05659-5","article-title":"Higher levels of markers for early atherosclerosis in anti-citrullinated protein antibodies positive individuals at risk for RA, a cross sectional study","volume":"44","author":"Hinkema","year":"2024","journal-title":"Rheumatol Int"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-eular.3245","article-title":"AB0344 Subclinical vascular damage and its association with acpa and rf in patients with rheumatoid arthritis","volume":"76","author":"Aguilar-Zamora","year":"2017","journal-title":"Ann Rheumatic Dis"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220577","article-title":"Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis","volume":"80","author":"Ocon","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead088","article-title":"Safety and efficacy associated with long-term low-dose glucocorticoids in rheumatoid arthritis: A systematic review and meta-analysis","volume":"62","author":"Palmowski","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224185","article-title":"Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: A population-based study","volume":"82","author":"So","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/art.41122","article-title":"Impact of cumulative inflammation, cardiac risk factors, and medication exposure on coronary atherosclerosis progression in rheumatoid arthritis","volume":"72","author":"Karpouzas","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1093\/rheumatology\/kez557","article-title":"Smoking cessation is associated with lower disease activity and predicts cardiovascular risk reduction in rheumatoid arthritis patients","volume":"59","author":"Roelsgaard","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: A report of the American College of Cardiology Solution Set Oversight Committee","volume":"80","author":"Writing","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112138-20240531-00360","article-title":"2024 Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis","volume":"63","year":"2024","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"B69","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004886","article-title":"Methotrexate inhibits glucocorticoids-induced osteoclastogenesis via activating IFN-gammaR\/STAT1 pathway in the treatment of rheumatoid arthritis","volume":"10","author":"Teng","year":"2024","journal-title":"RMD Open"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152031","article-title":"Methotrexate use reduces mortality risk in rheumatoid arthritis: A systematic review and meta-analysis of cohort studies","volume":"55","author":"Xu","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.12.034","article-title":"Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated","volume":"78","author":"Atallah","year":"2023","journal-title":"J Hepatol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1124\/pr.54.4.599","article-title":"Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease","volume":"54","author":"De Bree","year":"2002","journal-title":"Pharmacol Rev"},{"key":"B75","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s13075-018-1768-8","article-title":"TNFalpha expressed on the surface of microparticles modulates endothelial cell fate in rheumatoid arthritis","volume":"20","author":"Barbati","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"B76","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/art.41095","article-title":"Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: A randomized controlled trial","volume":"72","author":"Giles","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13681","article-title":"Cardiovascular risk in rheumatoid arthritis patients treated with targeted synthetic and biological disease-modifying antirheumatic drugs: A multi-centre cohort study","volume":"294","author":"Tong","year":"2023","journal-title":"J Intern Med"},{"key":"B78","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1136\/annrheumdis-2020-eular.4327","article-title":"FRI0101 Effects of IL6 inhibitors on the incidence of major adverse cardiovascular events in rheumatoid arthritis patients: A systematic review with meta analysis","volume":"79","author":"Marais","year":"2020","journal-title":"Ann Rheumatic Dis"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222543","article-title":"Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: Results from the open-label, randomised controlled ORAL Surveillance trial","volume":"82","author":"Curtis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222259","article-title":"Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: A post hoc analysis from ORAL Surveillance","volume":"82","author":"Charles-Schoeman","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01062-9","article-title":"Efficacy and safety of JAK inhibitors in rheumatoid arthritis: Update for the practising clinician","volume":"20","author":"Szekanecz","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212392","article-title":"Implementation of the EULAR cardiovascular risk management guideline in patients with rheumatoid arthritis: Results of a successful collaboration between primary and secondary care","volume":"77","author":"Weijers","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.191326","article-title":"Benefits of methotrexate use on cardiovascular disease risk among rheumatoid arthritis patients initiating biologic disease-modifying antirheumatic drugs","volume":"48","author":"Xie","year":"2021","journal-title":"J Rheumatol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvp072","article-title":"Sulfasalazine induces haem oxygenase-1 via ROS-dependent Nrf2 signalling, leading to control of neointimal hyperplasia","volume":"82","author":"Kim","year":"2009","journal-title":"Cardiovasc Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223302","article-title":"Reducing cardiovascular risk with immunomodulators: A randomised active comparator trial among patients with rheumatoid arthritis","volume":"82","author":"Solomon","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.93465","article-title":"Antirheumatic drug leflunomide attenuates atherosclerosis by regulating lipid metabolism and endothelial dysfunction via DHODH\/AMPK signaling pathway","volume":"20","author":"Jiang","year":"2024","journal-title":"Int J Biol Sci"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.4078\/jrd.2024.0104","article-title":"Risk of acute myocardial infarction associated with anti-rheumatic agents in patients with rheumatoid arthritis: A nationwide population-based case-control study","volume":"32","author":"Ahn","year":"2025","journal-title":"J Rheum Dis"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110848","article-title":"The mechanisms of hydroxychloroquine in rheumatoid arthritis treatment: Inhibition of dendritic cell functions via Toll like receptor 9 signaling","volume":"132","author":"Han","year":"2020","journal-title":"BioMed Pharmacother"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.859260","article-title":"Hydroxychloroquine alleviates EAU by inhibiting uveitogenic T cells and ameliorating retinal vascular endothelial cells dysfunction","volume":"13","author":"Hu","year":"2022","journal-title":"Front Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24850","article-title":"Hydroxychloroquine use and cardiovascular events among patients with systemic lupus erythematosus and rheumatoid arthritis","volume":"75","author":"Jorge","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B91","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10557-022-07387-z","article-title":"Hydroxychloroquine and cardiovascular events in patients with rheumatoid arthritis","volume":"38","author":"Cordova Sanchez","year":"2024","journal-title":"Cardiovasc Drugs Ther"},{"key":"B92","article-title":"Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis","volume":"32","author":"Jacobsson","year":"2005","journal-title":"J Rheumatol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209784","article-title":"Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis","volume":"76","author":"Low","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B94","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3892\/etm.2021.10981","article-title":"Influence of anti-TNF therapy and homocysteine level on carotid intima-media thickness in rheumatoid arthritis patients","volume":"23","author":"Anghel","year":"2022","journal-title":"Exp Ther Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211030809","article-title":"Factors associated with risk of major adverse cardiovascular events in patients with rheumatoid arthritis: A nationwide, population-based, case-control study","volume":"13","author":"Chen","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200916","article-title":"Soluble vascular biomarkers in rheumatoid arthritis and ankylosing spondylitis: Effects of 1-year antitumor necrosis factor-alpha therapy","volume":"48","author":"Pusztai","year":"2021","journal-title":"J Rheumatol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.2626","article-title":"OP0114 Short- and longer-term risks for acute coronary syndrome in patients with rheumatoid arthritis starting treatment with disease-modifying anti-rheumatic drugs. A collaborative observational head-to-head study across five Nordic rheumatology registers","volume":"80","author":"Delcoigne","year":"2021","journal-title":"Ann Rheumatic Dis"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2013.04.031","article-title":"Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis","volume":"229","author":"Strang","year":"2013","journal-title":"Atherosclerosis"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252212425","article-title":"Interleukin-6: Cardiovascular aspects of long-term cytokine suppression in patients with rheumatoid arthritis","volume":"25","author":"Gerasimova","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1002\/art.38982","article-title":"The efficacy of abatacept in reducing synovial T cell activation by CD1c myeloid dendritic cells is overruled by the stimulatory effects of T cell-activating cytokines","volume":"67","author":"Moret","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13075-024-03323-8","article-title":"Long-term effects of abatacept on atherosclerosis and arthritis in older vs. younger patients with rheumatoid arthritis: 3-year results of a prospective, multicenter, observational study","volume":"26","author":"Yamada","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001657","article-title":"The impact of biologic drugs on high-density lipoprotein cholesterol efflux capacity in rheumatoid arthritis patients","volume":"28","author":"Cacciapaglia","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204405","article-title":"Sarilumab, a fully human monoclonal antibody against IL-6Ralpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial","volume":"73","author":"Huizinga","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B105","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13075-020-02163-6","article-title":"Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes","volume":"22","author":"Gabay","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"B106","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s13075-020-02229-5","article-title":"Interleukin-6 receptor blockade or TNFalpha inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials","volume":"22","author":"Genovese","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"B107","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3390\/biom12101483","article-title":"Effects of one-year tofacitinib therapy on lipids and adipokines in association with vascular pathophysiology in rheumatoid arthritis","volume":"12","author":"Czokolyova","year":"2022","journal-title":"Biomolecules"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101009","article-title":"Baricitinib counteracts metaflammation, thus protecting against diet-induced metabolic abnormalities in mice","volume":"39","author":"Collotta","year":"2020","journal-title":"Mol Metab"},{"key":"B110","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/art.43042","article-title":"Neutrophil activation markers and rheumatoid arthritis treatment response to the JAK1\/2 inhibitor baricitinib","volume":"77","author":"Kuley","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221276","article-title":"Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database","volume":"81","author":"Taylor","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13688","article-title":"Upadacitinib: Mechanism of action, clinical, and translational science","volume":"17","author":"Mohamed","year":"2024","journal-title":"Clin Transl Sci"},{"key":"B113","doi-asserted-by":"publisher","first-page":"9736","DOI":"10.1038\/s41598-025-94894-2","article-title":"Comparison of anti-inflammatory and anti-angiogenic effects of JAK inhibitors in IL-6 and TNFalpha-stimulated fibroblast-like synoviocytes derived from patients with RA","volume":"15","author":"Suda","year":"2025","journal-title":"Sci Rep"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-004007","article-title":"Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study","volume":"10","author":"Fleischmann","year":"2024","journal-title":"RMD Open"},{"key":"B115","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1136\/annrheumdis-2020-eular.2494","article-title":"FRI0344 The long-term effect of treating psoriatic arthritis with the Janus kinase 1-selective inhibitor filgotinib on lipid profiles: An analysis of the EQUATOR and EQUATOR2 trials","volume":"79","author":"Husni","year":"2020","journal-title":"Ann Rheumatic Dis"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-eular.5799","article-title":"THU0206 The jak1-selective inhibitor filgotinib reduces multiple markers of inflammation linked to various pathologic cell types and processes in rheumatoid arthritis patients","volume":"76","author":"Taylor","year":"2017","journal-title":"Ann Rheumatic Dis"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004857","article-title":"Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study","volume":"11","author":"Westhovens","year":"2025","journal-title":"RMD Open"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1790634\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:43:30Z","timestamp":1776059010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1790634\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":117,"alternative-id":["10.3389\/fimmu.2026.1790634"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1790634","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"article-number":"1790634"}}